Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
128.00
+4.00 (3.23%)
Mar 10, 2026, 12:35 PM JST
-46.44%
Market Cap 9.04B
Revenue (ttm) n/a
Net Income (ttm) -1.46B
Shares Out 72.93M
EPS (ttm) -21.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 787,500
Average Volume 4,084,045
Open 126.00
Previous Close 124.00
Day's Range 125.00 - 131.00
52-Week Range 98.00 - 284.00
Beta n/a
RSI 51.90
Earnings Date Apr 10, 2026

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.